Immunome (IMNM) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immunome (IMNM) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 36.8% versus a loss of 12.5%. Over five years, IMNM leads with a +11.0% price change compared with -75.2% for TSHA. Immunome is the larger company by market cap ($2.31 billion vs $1.46 billion), about 1.6 times the size, while Taysha Gene Therapies is growing revenue faster (+17.3% vs -23.2%).
Taysha Gene Therapies converts more of its revenue into profit, with a net margin of -1115.3% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | TSHA |
|---|---|---|
| Share price | $19.55 | $4.49 |
| Market cap | $2.31B | $1.46B |
| 1-day change | +1.24% | +1.35% |
| YTD return | -8.99% | -19.45% |
| 1-year return | +36.81% | -12.45% |
| 5-year return | +11.02% | -75.22% |
| EPS (TTM) | $-2.52 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $9.77M |
| Revenue growth (YoY) | -23.23% | +17.28% |
| Net income (latest FY) | $-212.39M | $-109.00M |
| Operating margin | -3228.83% | -1130.65% |
| Net margin | -3059.99% | -1115.27% |
| 52-week high | $30.06 | $7.30 |
| 52-week low | $13.54 | $3.69 |
| Distance from 52-week high | -34.96% | -38.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +80.05% | +189.53% |
| Average volume | 1.21M | 3.29M |
| Shares outstanding | 118.00M | 325.83M |
| Employees | 247 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed TSHA by 49.3 percentage points over the past year.
- Taysha Gene Therapies is more profitable, keeping -1115.3 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Taysha Gene Therapies grew revenue faster in its latest fiscal year (+17.28% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
IMNM vs TSHA FAQ
Which is bigger, Immunome or Taysha Gene Therapies?
Immunome (IMNM) is larger, with a market capitalization of $2.31B compared with $1.46B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, IMNM or TSHA?
IMNM returned +36.81% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Taysha Gene Therapies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Immunome and Biotechnology: Biological Products (No Diagnostic Substances) for Taysha Gene Therapies.